Amato L, Minozzi S, Pani PP et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003352. doi: 10.1002/14651858.CD003352.pub3.
Ambre J. The urinary excretion of cocaine and metabolites in humans: a kinetic analysis of published data. J Anal Toxicol, 1985; 9: 241-245.
Baumann BM, Perrone J, Hornig SE et al. Randomized, double blind, placebo-controlled trail of diazepam, nitroglicerin, or both for treatment of cocaine-associated acute coronary syndrome. Acad Emerg Med 2000; 7: 878-885.
Benowitz N. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol, 1993; 72: 3-12.
Berkowitz B, Spector S. Evidence for active immunity to morphine in mice. Science 1972;, 178: 1290-2.
Braunwald E et al. ACC/AHA Guidelines for Unstable Angina. J Am Coll Cardiol 2000; 36: 970-1062.
Bricolo F, Faccio M, Serpelloni G. Trattamenti farmacologici dei disturbi psichici correlati all’uso di cocaina In Cocaina: manuale di aggiornamento tecnico-scientifico. Dipartimento Nazionale per le Politiche Antidroga, 2006, Capitolo 6, pp. 305-395.
Brookoff D, Rotondo MF, Shaw LM et al. Cocaethylene levels in patients who test positive for cocaine. Ann Emerg Med 1996; 27: 316-320.
Chakko S, Fernandez A, Mellman TA et al. Cardiac manifestations of cocaine abuse: a cross-sectional study of asymptomatic men chronically abusing “crack” cocain. J Am Coll Cardiol 1992; 20: 1168-76.
Chakko S, Myerburg RJ. Cardiac complications of cocaine abuse. Clin Cardiol 1995; 18: 67-72.
Damodaran S. Cocaine and beta-blockers: the paradigm. β-blockers for chest pain associated with recent cocaine use. Eur J Intern Med. 2010; 21: 84-6.
Faccio M et al. Trattamenti sperimentali per i disturbi correlati all’uso di cocaina In Cocaina: manuale di aggiornamento tecnico-scientifico. Dipartimento Nazionale per le Politiche Antidroga, 2006, Capitolo 6, pp. 317-331.
Farre M, de la Torre R, Gonzalez ML et al. Cocaine and alcohol interactions in humans: neuroendocrin effects and cocaethylene metabolism. J Pharmacol Exp Ther, 1997; 283: 164-76.
Fox AW. More on rhabdomyolysis associated with cocaine intoxication. N Engl J Med 1989; 321: 1271
Fox BS, Kantak KM, Edwards MA et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine 1996; 2:1129-32.
Hatsukami D K, Rennard S, Jorenby D et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Therapeut. 2005;78:456-7.
Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine-Associated Chest Pain (COCHPA) Study Group. AcadEmerg Med 1994a; 1: 330-339.
Hollander JE, Hoffman RS, Gennis P, et al. Nitroglycerin in the treatment of cocaine associated chest pain: clinical safety and efficacy. J Toxicol Clin Toxicol 1994b;32:243-56.
Hollander JE, Hoffman RS, Burstein JL et al. Cocaine-associated myocardial infarction. Mortality and complications. Cocaine-Associated Myocardial Infarction Study Group. Arch Intern Med 1995; 155: 1081-86.
Hollander JE, Hoffman RS. Cocaine. In Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Hoffman RS (eds): Goldfrank’sToxicologic Emergencies. Appleton & Lange, Stamford, 6th ed, 1998, pp 1071-1089.
Honderick T, Williams D, Seaberg D et al. Prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med. 2003;21:39-42.
Ibrahim M, Maselli DJ, Hasan R et al. Safety of β-blockers in the acute management of cocaine-associated chest pain. Am J Emerg Med. 2012 Oct 30.doi:pii: S0735-6757(12)00490-1. 10.1016/j.ajem.2012.09.027.
Kampman K. M., Medications for cocaine abuse – Psychiatric Times – February 2005 – Vol. XXII – Issue 2.
Kendler KS, Prescott CA. Cannabis use, abuse, and dependence in a population based sample of female twins. Am J Psychiatry. 1988;155:1016-22.
Kendler KS, Prescott CA. Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. Am J Psychiatry. 1999;156:223-8.
Kendler KS, Jacobson KC, Prescott CA et al. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry. 2003; 160:687-95.
Kerns W II, Garvey L, Owens J. Cocaine-induced wide complex dysrhythmia. J Emerg Med 1997; 15: 321-9.
Lange RA, Cigarroa RG, Flores ED et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990 ;112:897-903.
Lange RA, Cigarroa Rg, Yancy CWJ et al. Cocaine induced coronary-artery vasoconstriction. N Engl J Med. 1989; 321: 1557-62.
Locatelli C, Giampreti A, Mazzoleni M et al. Linee Operative per la diagnosi, il trattamento e la riabilitazione delle persone dipendenti da cocaina. Presidenza del Consiglio dei Ministri, Ministro per la Cooperazione Internazionale DPA, 2012 Cap 2.2 pag:128-135.
Locatelli C, Lonati D, Petrolini V et al. Dopo una notte in discoteca. Problemi diagnostico-terapeutici nella sindrome coronarica acuta da uso di cocaina. Decidere in Medicina, 2003; 5: 16-30
Martell BA, Mitchell E, Poling J et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 2005;58: 158-64.
McCord J, Jneid H, Hollander JE et al. American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008;117:1897-907.
Merigian KS, Roberts JR. Cocaine intoxication: hyperpyrexia, rhabdomyolysis and acute renal failure. J Toxicol Clin Toxicol 1987; 25: 135-148.
MIXMAG 2012, MixmagGuardiandrugssurvey disponibile al sito www.mixmag.net/drugssurvey (ultimo accesso 7 marzo 2013).
Morrison LJ et al. 2010 International Consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 8: Advanced Life Support. Circulation, 2010; 122: S345-S421.
Mycek MJ, Harvey RA, Champe PC, editors. Lippincott’s illustrated reviews: Pharmacology. 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2000.
Nademanee K, Gorelick DA, Josephson MA, et al. Myocardial ischemia during cocaine withdrawal. Ann Intern Med 1989; 111: 876-880.
Pan Y, Gao D, Yang W, et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. – Proc Natl Acad Sci U S A. 2005;102:16656-61.
Phillips K, Luk A, Soor GS, et al. Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options. Am J Cardiovasc Drugs. 2009;9:177-196.
Polosa R, Benowitz, N. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends in Pharmacological Sciences. 2011;32: 281-9.
Relazione annuale 2012: evoluzione del fenomeno della droga in Europa. Capitolo 5, Cocaina e cocaina crack. 2012, pp 66-75.
Serpelloni G, Piemonte M. Uso di cocaina e lesioni distruttive facciali: linee di indirizzo per gli specialisti otorinolaringoiatri. Italian Journal on Addiction 2011; 11: 1-2.
Shen X, Orson F M, Kosten TR. Anti-addiction vaccines. F1000 Medicine Reports 2011;3: 20.
Smith JA, Mo Q, Guo H, et al. Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Brain Res Bull 1995; 683: 264-69.
Weiss RD. Protracted elimination of cocaine metabolites in long term high dose cocaine abuse. Am J Med 1998; 85: 879-80.
Welch RD, Todd K, Krause GS. Incidence of cocaine associated rhabdomyolysis. Ann Emerg Med 1991; 20: 154-7.
Wilbert-Lampen U, Selinger C, Zilker T et al. Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: reversal by co-incubation with sigma-receptor antagonists. Circulation 1998; 98: 385-90.
Zhan CG, Gao D. Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine. Biophys J. 2005;89:3863-72.
